Fig. 2From: Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world studyA Progression-free survival and (B) overall survival from the start of EGFR-TKI according to types of tyrosine kinase inhibitors. Exon 19 deletion: 130 patients, others: 106 patients (L858R: 83, uncommon mutations: 18, dual mutations: 5). Censoring was indicated by vertical linesBack to article page